GSK's share price rose 6% after settling 93% of Zantac cases, impacting Q3 earnings; forward non-GAAP P/E remains reasonable ...

Shares slipped in New York and Europe Thursday as the latest US inflation report strengthened the case for a slower pace of ...

The settlement, which is at the low end of Jefferies analysts’ $2 billion to $3.5 billion estimate, will resolve 93% of the ...

Lenders report that default rates on secured loans to UK households increased in Q3 2024 and are expected to increase again ...

The latest health news includes Illumina's launch of affordable gene sequencers, Pfizer's promising cancer drug trials, CVS ...

UK-based pharmaceutical giant GSK, or GlaxoSmithKline, has announced that it has agreed to settle nearly 80,000 state-level ...

GSK has settled lawsuits in the US that alleged the drugmaker’s now-discontinued heartburn drug Zantac triggered cancer ...

Traders around the word awaited U.S. inflation data for September—and the implications it will have for rate cuts at the ...

GSK shares top the Stoxx Europe 600 index on Thursday after the pharmaceutical company agreed to pay up to $2.2 billion to settle thousands of U.S. lawsuits over claims its discontinued heartburn ...

GlaxoSmithKline (GSK) saw its shares jump more than 6% after the pharmaceutical giant announced a settlement of up to $2.2 ...

GSK shares in London jumped 5% Thursday after the British drug giant said it has resolved most of the U.S. lawsuits it faced ...